Adicet Bio, Inc. discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. Lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma.
Market Cap | 626.868 Million | Shares Outstanding | 40.004 Million | Avg 30-day Volume | 294.308 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -1.01 |
Price to Revenue | 24.9407 | Debt to Equity | 0.0 | EBITDA | -38.779 Million |
Price to Book Value | 4.0656 | Operating Margin | -218.90740000000002 | Enterprise Value | 351.9 Million |
Current Ratio | 4.464 | EPS Growth | 0.619 | Quick Ratio | 4.209 |
1 Yr BETA | 1.8853 | 52-week High/Low | 21.17 / 6.25 | Profit Margin | -204.8707 |
Operating Cash Flow Growth | -49.028 | Altman Z-Score | 4.9826 | Free Cash Flow to Firm | -176.001 Million |
Please sign in first
none
15.3 Thousand total shares from 3 transactions
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
SCHOR CHEN PRESIDENT & CEO |
|
197,553 | 2022-08-04 | 5 |
HARVEY BRIAN NICHOLAS CHIEF FINANCIAL OFFICER |
|
65,912 | 2022-08-04 | 5 |
HEALEY DON CHIEF TECHNOLOGY OFFICER |
|
63,401 | 2022-08-04 | 5 |
GALIMI FRANCESCO SVP & CHIEF MEDICAL OFFICER |
|
70,384 | 2022-08-04 | 6 |
AFTAB BLAKE CHIEF SCIENTIFIC OFFICER |
|
49,434 | 2022-08-04 | 11 |
|
18,500 | 2022-06-02 | 1 | |
|
18,500 | 2022-06-02 | 2 | |
|
18,500 | 2022-06-02 | 3 | |
|
18,500 | 2022-06-02 | 1 | |
|
18,500 | 2022-06-02 | 3 | |
|
18,500 | 2022-06-02 | 5 | |
|
18,500 | 2022-06-02 | 1 | |
|
638,942 | 2021-12-10 | 1 | |
ABBOT STEWART SEE REMARKS |
|
5,000 | 2021-06-11 | 0 |
|
7,232,856 | 2021-02-12 | 1 | |
|
7,232,856 | 2021-02-12 | 0 | |
KLICKSTEIN LLOYD CHIEF INNOVATION OFFICER |
|
0 | 2021-02-12 | 0 |
KREHLIK CARRIE CHIEF HUMAN RESOURCES OFFICER |
|
0 | 2021-02-12 | 0 |
|
0 | 2020-09-15 | 0 | |
|
0 | 2020-09-15 | 0 | |
|
0 | 2020-06-03 | 0 | |
|
0 | 2020-06-03 | 0 | |
|
0 | 2020-06-03 | 0 | |
|
0 | 2020-06-03 | 0 | |
|
0 | 2020-06-03 | 0 | |
|
2,119,696 | 2019-12-18 | 0 | |
MCCABE JOHN J VICE PRESIDENT, FINANCE |
|
12,867 | 2019-12-06 | 0 |
MANNICK JOAN CHIEF MEDICAL OFFICER |
|
2,004,585 | 2019-12-06 | 0 |
|
4,830,387 | 2018-01-30 | 1 | |
|
3,164 | 2014-05-13 | 0 | |
ROSEN DAVID B. SR. V.P. - RISING PHARMA |
|
1,007,500 | 2012-02-17 | 0 |
GUCCIONE SALVATORE J SR PRESIDENT AND COO |
|
40,936 | 2012-02-16 | 0 |
GOLD RONALD PRESIDENT & COO - RISING PHARM |
|
1,041,000 | 2011-11-29 | 0 |
EILENDER ALBERT L CHAIRMAN & CHIEF EXEC. OFFICER |
|
90,606 | 2011-11-25 | 0 |
|
11,746 | 2009-01-13 | 0 | |
ROTH DOUGLAS A CFO, SECRETARY, TREASURER |
|
13,521 | 2007-04-09 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2022-08-08 20:26:23 -0400 | 2022-08-04 | A | 16,000 | a | 68,934 | direct | -3.7725 | 0.0 | 1 | -3.7725 | 2 | |||||
2022-08-08 20:26:23 -0400 | 2022-08-04 | F | 5,533 | $18.25 | d | 63,401 | direct | -3.7725 | 0.0 | 1 | -3.7725 | 2 | ||||
2022-08-08 20:27:44 -0400 | 2022-08-04 | A | 16,000 | a | 70,608 | direct | -3.7725 | 0.0 | 1 | -3.7725 | 2 | |||||
2022-08-08 20:27:44 -0400 | 2022-08-04 | F | 4,696 | $18.25 | d | 65,912 | direct | -3.7725 | 0.0 | 1 | -3.7725 | 2 | ||||
2022-08-08 20:29:15 -0400 | 2022-08-04 | A | 16,000 | a | 54,967 | direct | -3.7725 | 0.0 | 1 | -3.7725 | 2 | |||||
2022-08-08 20:29:15 -0400 | 2022-08-04 | F | 5,533 | $18.25 | d | 49,434 | direct | -3.7725 | 0.0 | 1 | -3.7725 | 2 | ||||
2022-08-08 20:31:03 -0400 | 2022-08-04 | A | 16,000 | a | 75,917 | direct | -3.7725 | 0.0 | 1 | -3.7725 | 2 | |||||
2022-08-08 20:31:03 -0400 | 2022-08-04 | F | 5,533 | $18.25 | d | 70,384 | direct | -3.7725 | 0.0 | 1 | -3.7725 | 2 | ||||
2022-08-08 20:32:56 -0400 | 2022-08-04 | A | 48,000 | a | 144,000 | direct | -3.7725 | 0.0 | 1 | -3.7725 | 2 | |||||
2022-08-08 20:32:56 -0400 | 2022-08-04 | F | 21,288 | $18.25 | d | 122,712 | direct | -3.7725 | 0.0 | 1 | -3.7725 | 2 | ||||
2022-08-05 18:43:54 -0400 | 2022-08-03 | S | 6,968 | $18.00 | d | 38,967 | direct | yes | -5.0689 | 0.0 | 1 | -5.0689 | 2 | |||
2022-08-03 16:16:08 -0400 | 2022-08-01 | S | 6,968 | $16.64 | d | 45,935 | direct | yes | 2.6849 | -14.137 | 2.6849 | 2 | -14.137 | 6 | ||
2022-08-08 20:32:56 -0400 | 2022-07-06 | G | 53,424 | d | 96,000 | direct | -3.7725 | 0.0 | 1 | -3.7725 | 2 | |||||
SCHOR CHEN - Director - Officer PRESIDENT & CEO see footnote |
2022-08-08 20:32:56 -0400 | 2022-07-06 | G | 53,424 | a | 143,260 | indirect | -3.7725 | 0.0 | 1 | -3.7725 | 2 | ||||
2022-07-07 17:12:16 -0400 | 2022-07-05 | S | 1,363 | $14.50 | d | 52,903 | direct | yes | -10.3226 | -2.2043 | 0.0 | 1 | -10.3226 | 2 |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
ADICET BIO INC ACET | 2022-08-12 22:15:03 UTC | 1.4496 | 0.8704 | 1000000 |
ADICET BIO INC ACET | 2022-08-12 21:45:04 UTC | 1.4496 | 0.8704 | 1000000 |
ADICET BIO INC ACET | 2022-08-12 21:15:04 UTC | 1.4496 | 0.8704 | 1000000 |
ADICET BIO INC ACET | 2022-08-12 20:45:04 UTC | 1.4496 | 0.8704 | 1000000 |
ADICET BIO INC ACET | 2022-08-12 20:15:05 UTC | 1.4496 | 0.8704 | 1000000 |
ADICET BIO INC ACET | 2022-08-12 19:45:03 UTC | 1.4496 | 0.8704 | 1000000 |
ADICET BIO INC ACET | 2022-08-12 19:15:05 UTC | 1.4496 | 0.8704 | 1000000 |
ADICET BIO INC ACET | 2022-08-12 18:45:03 UTC | 1.4496 | 0.8704 | 1000000 |
ADICET BIO INC ACET | 2022-08-12 18:15:04 UTC | 1.4496 | 0.8704 | 1000000 |
ADICET BIO INC ACET | 2022-08-12 17:45:04 UTC | 1.4496 | 0.8704 | 1000000 |
ADICET BIO INC ACET | 2022-08-12 17:15:05 UTC | 1.4496 | 0.8704 | 1000000 |
ADICET BIO INC ACET | 2022-08-12 16:45:04 UTC | 1.4502 | 0.8698 | 1000000 |
ADICET BIO INC ACET | 2022-08-12 16:15:04 UTC | 1.4502 | 0.8698 | 1000000 |
ADICET BIO INC ACET | 2022-08-12 15:45:04 UTC | 1.4502 | 0.8698 | 1000000 |
ADICET BIO INC ACET | 2022-08-12 15:15:05 UTC | 1.4502 | 0.8698 | 1000000 |
ADICET BIO INC ACET | 2022-08-12 14:45:04 UTC | 1.4502 | 0.8698 | 1000000 |
ADICET BIO INC ACET | 2022-08-12 14:15:05 UTC | 1.4502 | 0.8698 | 1000000 |
ADICET BIO INC ACET | 2022-08-12 13:45:04 UTC | 1.4569 | 0.8631 | 1000000 |
ADICET BIO INC ACET | 2022-08-12 13:15:04 UTC | 1.4569 | 0.8631 | 1000000 |
ADICET BIO INC ACET | 2022-08-12 12:45:04 UTC | 1.4569 | 0.8631 | 1000000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|